-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Tiantan Biology (600161.SH) issued an announcement. Recently, “Human Coagulation Factor IX” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. (“Chengdu Rongsheng”), a subsidiary of the company, completed phase III clinical trials and obtained a clinical trial summary report.

Zhitongcaijing·10/08/2026 10:41:10
Listen to the news
Zhitong Finance App News, Tiantan Biology (600161.SH) issued an announcement. Recently, “Human Coagulation Factor IX” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. (“Chengdu Rongsheng”), a subsidiary of the company, completed phase III clinical trials and obtained a clinical trial summary report.